Articles from Overture Life

Overture Life, the global leader in automated IVF and the first company to achieve live births from both robotic fertilization and robotic egg freezing, announced that the company has secured CE Mark certification for its DaVitri platform to expand access to automated in vitro fertilization (IVF) technology. DaVitri is now the first automation device with regulatory clearance for freezing unfertilized eggs in either the EU or the U.S., and the first freezing system granted approval with a validated claim for post-thaw blastocyst development rates. The milestones provide the company with the support needed to commercialize in Europe and the regulatory clearance to bring DaVitri to continental Europe as well as the UK and Turkey which also accept CE mark.

Overture Life, the company behind the world's first babies born from robotic fertilization and robotic egg freezing, today announced the opening of its Dallas facility at 4621 Ross Avenue in The Bogart Building. The site will run non-invasive, CLIA-licensed embryo-assessment testing that analyzes molecules in the fluid surrounding embryos (metabolomics) with machine-learning support, giving fertility teams objective data to inform embryo selection without a biopsy. It will also serve as Overture's U.S. clinical operations headquarters.

Overture Life, the innovator modernizing IVF to optimize reproductive freedom, announced the first commercial sale of an automated in vitro fertilization (IVF) platform to Memorial Hospital Istanbul, home to one of Europe’s leading fertility centers. Overture’s ICSI.A platform automates a complex fertilization process known as piezo-assisted intracytoplasmic sperm injection (piezo-ICSI), which uses electric pulses to fertilize eggs more gently than manual injection methods. Overture’s ICSI.A enabled the first live births resulting from an automated fertilization1, in 2023. Memorial Hospital Istanbul will use the devices to simplify thousands of IVF cycles per year, with the additional efficiency expected to grow its capacity even further.

Overture Life, the leader in automated IVF technology that delivered the first live births in the world from automated fertilization and egg freezing, today announced the appointment of Matthew Combs as Chief Commercial Officer (CCO). Combs joins Overture to drive global expansion amid rising domestic and international demand for IVF automation technology that directly addresses the embryologist shortages worldwide. In the newly created role, Combs will lead the company’s global commercialization as it expands access to technology that automates fertilization and egg freezing processes previously done by hand. These include the ICSI.A, the world’s first robot for automated fertilization, and the DaVitri, for automated, consistent, high-quality vitrification that will expand egg freezing beyond specialized IVF facilities. Combs will focus on scaling Overture Life’s fertility technologies to meet growing clinic demand.

Overture Life, the innovator modernizing IVF to optimize reproductive freedom, announces the launch of its DaVitri platform for fertility preservation for Brazil’s in vitro fertilization (IVF) clinics after being cleared for commercial use as a class I medical device by the nation’s National Health Surveillance Agency (ANVISA). This latest marketing authorization makes Brazil the sixth country in South and Central America where DaVitri can be used to automate vitrification, following another recent launch in Peru. Embryologists in the two countries now join counterparts in Panama, Chile, Dominican Republic, and Argentina in improving the quality and consistency of the delicate vitrification steps, using DaVitri to help standardize processes and, ultimately, reduce the number of IVF cycles required to have a healthy baby.

Overture Life today announced a $20.6 million strategic round, bringing its total funding to $57 million from leading industry investors, to support additional clinical research and product development designed to make IVF affordable to more people. The company is also announcing its newly achieved CLIA (Clinical Laboratory Improvement Amendments) license in the United States to meet federal clinical laboratory standards for m|z, its AI-powered, non-invasive metabolomic test for embryo selection. These latest milestones reinforce Overture’s commitment to demonstrating scientific rigor, securing regulatory support, and prioritizing patient safety. They also pave the way for the launch of DaVitri, an advanced embryology platform that automates egg freezing (vitrification) and embryo warming under reproducible, data-driven protocols.